Skip to content

A Phase IIa Study of thrombolysis with rhPro-UK in Patients With Acute Ischaemic Stroke

A Time-window Stratified,Randomised, Open-label, Controlled, Multicentered Phase IIa Trial to Assess the Efficacy and Safety of Thrombolysis with Recombinant Human Prourokinase in the patients with Acute Acute Ischaemic Stroke

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016519
Enrollment
Unknown
Registered
2018-06-06
Start date
2016-12-08
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke

Interventions

PUK50(4.5h) group:50mg pro-UK for patients within 4.5h of AIS
PUK35(4.5h) group:35mg pro-UK for patients within 4.5h of AIS
PUK50(6h) group:50mg pro-UK for patients from 4.5h to 6h of AIS onset
PUK35 (6h) group:35mg pro-UK for patients from 4.5h to 6h of AIS onset
RTPA (4.5h) group:0.9mg/kg rt-PA for patients within 4.5h of AIS

Sponsors

Xuanwu Hospital Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Ischemic stroke with symptoms of neurological deficits; 2. Aged 18 to 80 years, male or female; 3. NIH Stroke Scale(NIHSS)scores of 4 to 25; 4. Treatment within 6 hours after stroke onset. Stroke onset time is defined as the last time a patient with no clinical neurological deficit,for patients who wake up with stroke symptoms, consider that stroke occurs when the patient begins to fall asleep; 5. The symptoms of stroke last at least 30 minutes without significant improvement before treatment; 6. CT shows negative or signs of early infarction; 7. Patients and/or their families are willing to participate in this study and agree to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. The duration from the onset of stroke symptoms to thrombolysis was > 6 hours; 2. CT shows multiple infarctions (low density> 1/3 cerebral hemisphere); 3. Intracranial hemorrhage or subarachnoid hemorrhage on baseline; 4. Transient ischemic attack; 5. Epileptic seizure when stroke onset; 6. Active visceral hemorrhage; 7. Intracranial tumor, arteriovenous malformation and aneurysm; 8. Stroke due to treatment of intracranial aneurysm or arteriovenous malformation by interventional therapy operation(Stroke due to diagnostic cerebral angiography or cardiac intervention should be treated); 9. Cardiogenic embolism; 10. Puncture in 1 week which can not be oppressed; 11. Major surgery or severe trauma within 2 weeks; 12. Intracranial surgery, intraspinal surgery or solid organ biopsy within 30 days; 13. Myocardial infarction history within 3 months; 14. Severe cerebral trauma or stroke history within 3 months; 15. Blood pressure is still out of control after aggressive antihypertensive treatment.Uncontrolled blood pressure is defined as systolic blood pressure= 180mmHg or diastolic blood pressure =100mmHg at least 10 minutes interval and repeated three times; 16. Heparin treatment within 48 hours (APTT above normal upper limit); 17. Taking anticoagulant drugs orally, and PT >15s or INR >1.7; 18. High risk of acute hemorrhage,including platelet count 22.2 mmol/L; 21. Patients with intracerebral hemorrhage history; 22. Pregnancy, lactating or menstrual women; 23. Patients with diabetic retinopathy history.

Design outcomes

Primary

MeasureTime frame
modified Rankin scale scores;

Secondary

MeasureTime frame
modified Rankin scale scores;NIHSS changes;Barthel Index;Recurrence of stroke within 7 day after treatment;

Countries

China

Contacts

Public ContactYuping Wang

Xuanwu Hospital Capital Medical University,

wangyuping01@sina.cn+86 010-83198899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026